ProQR Therapeutics (NASDAQ:PRQR) Upgraded at Citigroup

Citigroup upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a neutral rating to a buy rating in a report released on Monday, Marketbeat.com reports. Citigroup currently has $4.00 price target on the biopharmaceutical company’s stock.

PRQR has been the topic of a number of other reports. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. JMP Securities restated a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Chardan Capital restated a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Finally, Oppenheimer began coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price target on the stock. One analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.17.

ProQR Therapeutics Price Performance

Shares of PRQR stock opened at $1.85 on Monday. The firm has a market cap of $151.11 million, a P/E ratio of -5.78 and a beta of 0.24. ProQR Therapeutics has a 1-year low of $1.61 and a 1-year high of $4.62. The firm has a fifty day moving average of $2.29 and a two-hundred day moving average of $2.62.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in ProQR Therapeutics during the 4th quarter valued at about $30,000. Invesco Ltd. acquired a new position in ProQR Therapeutics during the 4th quarter valued at about $32,000. Alpine Global Management LLC acquired a new position in ProQR Therapeutics during the 4th quarter valued at about $39,000. Two Sigma Securities LLC acquired a new position in ProQR Therapeutics during the 4th quarter valued at about $40,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of ProQR Therapeutics in the 4th quarter worth approximately $54,000. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).